utoimmune hepatitis is a liver disease of unknown etiology often affecting young women. It is a chronic hepatitis characterized by hypergammaglobulinemia and serum autoantibodies, and is unrelated to viral infection, hepatotoxic drugs or hereditary disorders. The natural outcome is generally poor, with cirrhosis at presentation in 50 to 90% of patients [1] .
The preferred treatment includes corticosteroids and azathioprine [1] . Remission is achieved in over 70% of cases and longterm treatment with azathioprine, with or without prednisolone, can prevent relapse [2, 3] . However, severe adverse effects occur in about 10% of patients treated with combination therapy, and in 44% of patients treated with high dose prednisone monotherapy [3] [4] [5] . For patients with drug toxicity or intolerance, a dose reduction or drug discontinuation may be necessary. Numerous second-line agents which have been used include cyclosporine, 6-mercaptopurine and tacrolimus [6] [7] [8] [9] [10] .
Ursodeoxycholic acid is the 7a-hydroxy epimer of chenodeoxycholic acid and has been reported to yield improvements in liver dysfunction due to cholestatic liver diseases, with few if any adverse effects. Ursodeoxycholic acid is now the reference therapy for primary biliary cirrhosis [11, 12] .
Ursodeoxycholic acid has rarely been tested in autoimmune hepatitis, although preliminary reports suggest that it might be effective [13] [14] [15] [16] [17] .
We report a case of well-documented typical type 1 autoimmune hepatitis in a patient intolerant to corticosteroid and azathioprine combination therapy, in whom long-term remission was obtained during ursodeoxycholic acid monotherapy.
Case report
In September 1992, a 37-year-old woman weighing 60 kg was admitted for fatigue associated with elevated serum alanine aminotransferase (ALT) activity (25 times the upper limit of normal (ULN)). Serum alkaline phosphatase and gamma-glutamyl transpeptidase levels were within the normal range. Type 1 autoimmune hepatitis was diagnosed on the basis of: (1) hypergammaglobulinaemia at 30 g/L, (2) positive antismooth muscle antibodies (1:1000 by immunofluorescence on unfixed 4 mm cryostat sections of rat liver, stomach and kidney), (3) periportal necroticoinflammatory lesions with lymphoplasmocytic infiltrate and mild portal fibrosis (figure 1) and 4) no other cause of liver disease. The patient did not consume alcohol or drugs, and had no markers of hepatitis A, B or C, cytomegalovirus or Epstein-Barr virus infection, Wilson's disease, a1-antitrypsin deficiency, or hemochromatosis. Serum antimitochondrial antibodies were not detected. Histologically, the interlobular and septal bile ducts were normal, and there was neither steatosis nor iron overload. Her HLA phenotype was A2/32 B27 Bw4 Cw2/w7 and DR4/4. Her score for diagnosis of autoimmune hepatitis was 16 (definite autoimmune hepatitis). Immunosuppressive therapy with corticosteroids (30 mg per day) and azathioprine (100 mg per day) was administered. Steroids were gradually reduced to a dose of 3 mg per day and were stopped in March 1994. One month later, despite continued azathioprine therapy, a relapse occurred with an increase in serum ALT (3 ULN); steroids (30 mg per day) were promptly reintroduced, leading to rapid recovery; the dose was gradually reduced to 2.5 mg per day and then stopped in December 1994 (figure 2). 7), hyaluronic acid 40 g/L (< 75 g/L), -2 macroglobulin 2 g/L (1.6-4), prothrombin index 80% and platelet count 180 000/mm3 were within the normal range [18] .
Obtention d'une rémission grâce à l'acide ursodésoxycholique chez une malade atteinte d'hépatite auto-immune de type 1 et résistante à l'azathioprine et à la corticothérapie

Discussion
We describe a complete biochemical and histological remission of type 1 autoimmune hepatitis in a middle-aged woman during ursodeoxycholic acid therapy. The diagnosis of type 1 autoimmune hepatitis in this patient was unequivocal. Concomitant primary biliary cirrhosis or overlap syndrome was ruled out by liver test results (elevated serum ALT and normal serum alkaline phosphatase and gammaglutamyltranspeptidase at diagno- sis), serum antimitochondrial and anti-gp210 antibody negativity and the absence of bile duct injury or ductopenia on histological examination of the liver [19] . The efficacy of ursodeoxycholic acid on this patient's autoimmune hepatitis is strongly suggested by the following observations: 1) successful control of relapse following steroid withdrawal, 2) successful control of a post-ursodeoxycholic acid relapse by ursodeoxycholic acid reintroduction, and 3) successful control of a relapse following a reduction in the ursodeoxycholic acid regimen by a slight dose increment.
Ursodeoxycholic acid therapy has led to improvements in many liver diseases, particularly primary biliary cirrhosis [11, 12, [21] [22] [23] . Data on ursodeoxycholic acid in autoimmune hepatitis are controversial. In a Japanese study of eight patients, levels of serum transaminases and immunological markers (serum IgG, -globulin, anti-smooth muscle antibodies) fell during ursodeoxycholic acid therapy at doses of 11.5-11.8 mg/kg [17] . Moreover, in 4 patients who underwent liver biopsy after one year on therapy, there was an improvement in necroticoinflammatory lesions but not in fibrosis. Interestingly, in one patient, serum ALT again increased after ursodeoxycholic acid withdrawal. All eight patients had mild type autoimmune hepatitis with few symptoms [17] . In a recent study by Czaja et al. [23] of a small cohort of patients, short term ursodeoxycholic acid therapy improved serum aspartate aminotransferase levels but did not improve the liver histology or facilitate steroid tapering or withdrawal. One explanation for these discrepancies may be differences in HLA-DR haplotypes. In the Japanese study, ursodeoxycholic acid induced a strong response in patients with the HLA-DR4 phenotype. This was also our patient's phenotype. In Czaja's study a high proportion of patients were HLA-DR17, which is associated with a poorer outcome [23] [24] [25] .
The pathogenesis of autoimmune hepatitis probably involves cellular immune-mediated cytotoxicity. A virus, drug or environmental toxin might be the triggering factor, or the disease might occur spontaneously with the emergence or the persistence of "forbidden clones" and loss of self-tolerance. The trigger may induce high levels of cytokines, which may regulate peptide presentation via MHC class I molecules and induce MHC class II molecule expression on hepatocytes [26] . The well-documented beneficial effect of ursodeoxycholic acid in primary biliary cirrhosis involves direct cytoprotection [26] . However, ursodeoxycholic acid also has other effects, such as protection of mitochondrial function, hypercholeresis and immunomodulation. In autoimmune hepatitis, ursodeoxycholic acid might reduce MHC class I antigen expression on hepatocytes, thereby inhibiting the immune-mediated liver cell damage by suppressing the interaction between antigen-presenting cells and T helper lymphocytes, and the subsequent activation of cytotoxic T lymphocytes. In the present casereport, and in the series by Nakamura et al. [16] , the histological recovery observed during ursodeoxycholic acid therapy was most marked when liver damage was initially mild (absence of septal fibrosis). To our knowledge, ursodeoxycholic acid has never been reported to improve severe autoimmune hepatitis. Another factor favoring response to ursodeoxycholic acid is the HLA-DR4 haplotype.
In conclusion, this case report suggests that ursodeoxycholic acid could significantly improve autoimmune hepatitis, and might be particularly useful in case of resistance or intolerance to conventional therapies, or as a first-line treatment of mild to moderate liver injury due to autoimmune hepatitis. Its possible efficacy in combination with steroids and/or azathioprine remains to be determined. The factors influencing the response to ursodeoxycholic acid in autoimmune hepatitis need to be clearly identified. 
